Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas

Julie Marie Vose, Cary Peterson, Philip Jay Bierman, Dennis D. Weisenburger, James Linder, Douglas Harrington, William P. Vaughan, Anne Kessinger, James Olen Armitage

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Advanced T-cell non-Hodgkin's lymphoma in adults has been found to have a poor outlook with conventional chemotherapy. To see if this extends to patients treated with high dose therapy and autologous hematopoietic stem cell transplantation, we reviewed the results with this treatment approach at our institution. From October, 1983, to May, 1988, 41 patients who underwent high-dose therapy and autologous hematopoietic stem cell transplant for recurrent non-Hodgkin's lymphoma were re-biopsied before transplantation to determine their immunophenotype. Seventeen of these patients were found to have a T-cell lymphoma, and 24 had a B-cell lymphoma. All patients were included in the intermediate or high grade non-Hodgkin's lymphoma categories, and none were histologically transformed from a low grade lymphoma. Analysis of the response to autologous transplantation in these two patient populations revealed a slightly better complete response rate for patients with T-cell lymphoma (ie, 59% versus 42%, P = NS). The actuarial 2-year survival was 35% in the T-cell group compared with 30% in the B-cell group (P = NS). The 2-year disease-free survival was 28% for the T-cell and 17% for the B-cell patients. Our results with autologous transplantation for salvage therapy revealed equivalent long-term survival and disease-free survival in both relapsed T- and B-cell non-Hodgkin's lymphoma.

Original languageEnglish (US)
Pages (from-to)424-431
Number of pages8
JournalBlood
Volume76
Issue number2
StatePublished - Jan 1 1990

Fingerprint

T-cells
Autologous Transplantation
B-Cell Lymphoma
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Bone
Cells
T-Lymphocytes
T-Cell Lymphoma
Stem cells
Therapeutics
Disease-Free Survival
Salvaging
Transplants
Chemotherapy
B-Lymphocytes
Salvage Therapy
Survival
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. / Vose, Julie Marie; Peterson, Cary; Bierman, Philip Jay; Weisenburger, Dennis D.; Linder, James; Harrington, Douglas; Vaughan, William P.; Kessinger, Anne; Armitage, James Olen.

In: Blood, Vol. 76, No. 2, 01.01.1990, p. 424-431.

Research output: Contribution to journalArticle

Vose, Julie Marie ; Peterson, Cary ; Bierman, Philip Jay ; Weisenburger, Dennis D. ; Linder, James ; Harrington, Douglas ; Vaughan, William P. ; Kessinger, Anne ; Armitage, James Olen. / Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. In: Blood. 1990 ; Vol. 76, No. 2. pp. 424-431.
@article{76ae85f247f241cebfb5bcd9a9544e8a,
title = "Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas",
abstract = "Advanced T-cell non-Hodgkin's lymphoma in adults has been found to have a poor outlook with conventional chemotherapy. To see if this extends to patients treated with high dose therapy and autologous hematopoietic stem cell transplantation, we reviewed the results with this treatment approach at our institution. From October, 1983, to May, 1988, 41 patients who underwent high-dose therapy and autologous hematopoietic stem cell transplant for recurrent non-Hodgkin's lymphoma were re-biopsied before transplantation to determine their immunophenotype. Seventeen of these patients were found to have a T-cell lymphoma, and 24 had a B-cell lymphoma. All patients were included in the intermediate or high grade non-Hodgkin's lymphoma categories, and none were histologically transformed from a low grade lymphoma. Analysis of the response to autologous transplantation in these two patient populations revealed a slightly better complete response rate for patients with T-cell lymphoma (ie, 59{\%} versus 42{\%}, P = NS). The actuarial 2-year survival was 35{\%} in the T-cell group compared with 30{\%} in the B-cell group (P = NS). The 2-year disease-free survival was 28{\%} for the T-cell and 17{\%} for the B-cell patients. Our results with autologous transplantation for salvage therapy revealed equivalent long-term survival and disease-free survival in both relapsed T- and B-cell non-Hodgkin's lymphoma.",
author = "Vose, {Julie Marie} and Cary Peterson and Bierman, {Philip Jay} and Weisenburger, {Dennis D.} and James Linder and Douglas Harrington and Vaughan, {William P.} and Anne Kessinger and Armitage, {James Olen}",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "76",
pages = "424--431",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas

AU - Vose, Julie Marie

AU - Peterson, Cary

AU - Bierman, Philip Jay

AU - Weisenburger, Dennis D.

AU - Linder, James

AU - Harrington, Douglas

AU - Vaughan, William P.

AU - Kessinger, Anne

AU - Armitage, James Olen

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Advanced T-cell non-Hodgkin's lymphoma in adults has been found to have a poor outlook with conventional chemotherapy. To see if this extends to patients treated with high dose therapy and autologous hematopoietic stem cell transplantation, we reviewed the results with this treatment approach at our institution. From October, 1983, to May, 1988, 41 patients who underwent high-dose therapy and autologous hematopoietic stem cell transplant for recurrent non-Hodgkin's lymphoma were re-biopsied before transplantation to determine their immunophenotype. Seventeen of these patients were found to have a T-cell lymphoma, and 24 had a B-cell lymphoma. All patients were included in the intermediate or high grade non-Hodgkin's lymphoma categories, and none were histologically transformed from a low grade lymphoma. Analysis of the response to autologous transplantation in these two patient populations revealed a slightly better complete response rate for patients with T-cell lymphoma (ie, 59% versus 42%, P = NS). The actuarial 2-year survival was 35% in the T-cell group compared with 30% in the B-cell group (P = NS). The 2-year disease-free survival was 28% for the T-cell and 17% for the B-cell patients. Our results with autologous transplantation for salvage therapy revealed equivalent long-term survival and disease-free survival in both relapsed T- and B-cell non-Hodgkin's lymphoma.

AB - Advanced T-cell non-Hodgkin's lymphoma in adults has been found to have a poor outlook with conventional chemotherapy. To see if this extends to patients treated with high dose therapy and autologous hematopoietic stem cell transplantation, we reviewed the results with this treatment approach at our institution. From October, 1983, to May, 1988, 41 patients who underwent high-dose therapy and autologous hematopoietic stem cell transplant for recurrent non-Hodgkin's lymphoma were re-biopsied before transplantation to determine their immunophenotype. Seventeen of these patients were found to have a T-cell lymphoma, and 24 had a B-cell lymphoma. All patients were included in the intermediate or high grade non-Hodgkin's lymphoma categories, and none were histologically transformed from a low grade lymphoma. Analysis of the response to autologous transplantation in these two patient populations revealed a slightly better complete response rate for patients with T-cell lymphoma (ie, 59% versus 42%, P = NS). The actuarial 2-year survival was 35% in the T-cell group compared with 30% in the B-cell group (P = NS). The 2-year disease-free survival was 28% for the T-cell and 17% for the B-cell patients. Our results with autologous transplantation for salvage therapy revealed equivalent long-term survival and disease-free survival in both relapsed T- and B-cell non-Hodgkin's lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=0025348859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025348859&partnerID=8YFLogxK

M3 - Article

C2 - 1973361

AN - SCOPUS:0025348859

VL - 76

SP - 424

EP - 431

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -